Millions of people take aspirin every day for the prevention of atherothrombotic cardiovascular events. Aspirin inhibits thrombus formation by irreversibly inactivating the cyclooxygenase (COX)-1 enzyme in platelets, thereby blocking platelet production of thromboxane A 2 , a potent vasoconstrictor and platelet agonist (1) . Multiple studies have reported that in some individuals the effectiveness of aspirin for cardiovascular prevention is limited by "resistance" to its antiplatelet effects (2) . Although the validity of aspirin resistance, as an entity, continues to be debated, observational studies consistently show that as many as one-third of individuals prescribed aspirin have less-than-expected inhibition of platelet function, which is independently associated with an increased risk of cardiovascular events (3) (4) (5) .
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So-called aspirin resistance can often be overcome simply by improving patient adherence or increasing the dose or frequency of aspirin treatment (6 -9), but there are also unequivocal causes of aspirin resistance, such as drug-drug interactions in which nonsteroidal anti-inflammatory drugs prevent access of aspirin to platelet COX-1 (2).
Suboptimal platelet inhibition by aspirin (aspirin resistance) is particularly common in patients undergoing coronary artery bypass graft (CABG) surgery and, in this setting, is often attributed to an increased rate of platelet production (by up to 80%) resulting in an increased fraction of active (not acetylated) platelet COX and an increased proportion of nonaspirinated platelets. Aspirin is administered once daily, and most platelets produced during the 24-h dosing interval remain uninhibited until the next dose, because aspirin has a half-life of only 13 to 19 min (10). In addition, Zimmermann et al. (11) reported that incomplete inhibition of platelet COX-1 by aspirin after CABG surgery, as measured by persistent thromboxane production and platelet aggregation in response to arachidonic acid, could not be overcome in vitro by high concentrations of aspirin (100 mol/l) that exceeded those in plasma after oral aspirin treatment. They suggested that aspirin resistance after CABG seemed to result from an impaired interaction of aspirin with platelet COX (11) , but the actual mechanism(s) responsible for reduced platelet-inhibitory effect of aspirin after CABG surgery has been uncertain until now.
In this issue of the Journal, Mattiello et al. (12) present preliminary data on a new, hitherto unrecognized mechanism of aspirin resistance that could explain suboptimal platelet inhibition by aspirin in patients who have undergone recent CABG surgery. Mattiello et al. (12) hypothesized that CABG surgery leads to an upregulation of the unidirectional transporter multidrug resistance protein-4 (MRP4) in the plasma membrane of platelets; the upregulated MRP4 increases active transport of aspirin, an organic ion, from the platelet cytosol to the outside of the cell; the concentration of aspirin in the cytosol falls; and there is less aspirin available to inhibit COX-1-dependent platelet aggregation ( Fig. 1) . Furthermore, Mattiello et al. hypothesized that pre-treatment with the MRP4 inhibitors, dipyridamole and Mk-571, would inhibit MRP4-mediated transport of aspirin out of the platelet and thereby promote accumulation of aspirin in platelets and aspirin-mediated inhibition of COX-1-dependent thromboxane production and platelet aggregation.
To test this hypothesis Mattiello et al. (12) performed a series of elegant experiments with platelet preparations obtained from patients undergoing CABG surgery and from healthy volunteers. In their first set of experiments, they used 14 C-labelled aspirin, fluorescent cyclic adenosine monophosphate (a known MRP4 substrate), and various MRP4 inhibitors to establish that: 1) aspirin is a substrate for MRP4; and 2) MRP4 inhibitors prevent platelet aspirin and salicylic acid (the metabolite of aspirin) transport into dense granules and out of the platelet, increase intra-platelet aspirin and salicylic acid concentrations, and enhance the COX-1-inhibitory effect of aspirin. Thromboxane is also a substrate for the MRP4 efflux pump, but Mattiello et al. (12) showed that suppression of thromboxane concentrations after the addition of an MRP4 inhibitor was due to enhanced aspirin action (i.e., greater COX-1 inhibition) rather than any important direct effect of MRP4 on thromboxane release. In a second set of experiments, Mattiello et al. (12) confirmed the role of MRP4 in aspirin transport with platelets obtained from an in vitro cell culture system and megakaryocytes transfected with a small interfering ribonucleic acid that interferes with expression of MRP4. Compared with platelets obtained from untransfected megakaryocytes, platelets obtained from MRP4 small interfering ribonucleic acid-transfected megakaryocytes demonstrated increased cytosolic concentrations of aspirin and salicylic acid and reduced concentrations of thromboxane, findings that are consistent with the role of MRP4 in aspirin transport.
The third set of experiments involved the use of immunoblot, immunoelectron microscopy, and immunofluorescence studies to demonstrate that-compared with platelets collected from healthy volunteers-platelets collected 5 and 10 days after procedure from patients undergoing CABG surgery had increased MRP4 expression. The MRP4 expression was preferentially localized at the plasma membrane on day 5 compared with day 10 after surgery.
Multidrug resistance proteins are adenosine triphosphatedependent efflux pumps localized in cellular plasma membranes that have broad substrate specificity for transport of endogenous anionic substances and play a key role in hepatobiliary, renal, and intestinal drug elimination (13) . One of 9 distinct multidrug resistance proteins, MRP4 is expressed in the membrane of platelet dense granules in platelets and, to a lesser extent, in the plasma membrane of platelets (14) as well as in red cells, the kidney, prostate, and liver (15) . Drug substrates for MRP4 include nucleoside analogues used in the treatment of human immunodeficiency virus as well as antibiotic and antineoplastic agents. Inhibition of MRP4 by dipyridamole could explain the enhanced thromboxane suppression that has previously been reported when dipyridamole is added to aspirin (16) . Genes encoding MRPs are highly polymorphic (17) , and variants leading to lack of functional protein account for hereditary conditions such as Dubin-Johnson syndrome (MRP2 deficiency) and pseudoxanthoma elasticum (MRP6 deficiency). To date, however, no disease has been directly linked to altered MRP4 activity.
Mattiello et al. (12) are the first to demonstrate that aspirin is a substrate for MRP4, and their data provide a plausible mechanism for post-CABG aspirin resistance and the attendant increase in risk of cardiovascular events (18) . As with so many new discoveries, these findings raise important new questions. What is the mechanism of upregulation of MRP4 after CABG surgery? Does MRP4 upregulation also occur in other high platelet production states (e.g., acute coronary syndromes, bleeding, sepsis) and contribute to the aspirin resistance that has been reported in patients with acute coronary syndrome and undergoing percutaneous coronary intervention and in patients with diabetes? From a therapeutic perspective, the most important question is whether MRP4-induced aspirin resistance can be overcome by more frequent doses of aspirin or by the use of an MRP4 inhibitor such as dipyridamole and, if so, whether this leads to an improvement in clinical outcomes? If the favorable effect of adding dipyridamole to aspirin in patients with previous ischemic stroke of arterial origin is mediated by inhibition of MRP4-mediated transport (19) , are there other, more potent inhibitors of MRP4-mediated transport-such as cilostazol (20) -that might further enhance the effectiveness of aspirin?
Further studies are clearly required to validate and extend the provocative findings by Mattiello et al. (12) concerning the role of MRP4 in post-CABG aspirin resistance. Molecular studies should ideally be performed in parallel with functional and biochemical studies to examine the potential role of MRP4 gene polymorphisms that alter the expression and function of the transporter as determinants of the occurrence and severity of aspirin resistance (17) . Confirmation of the causal role of MRP4 in aspirin resistance could give rise to new more effective antiplatelet strategies for patients undergoing CABG surgery, thereby potentially reducing the very high rates of graft failure and major Before coronary artery bypass graft (CABG) surgery, there is minimal multidrug resistance protein 4 (MRP4) expression on the plasma membrane (A). After CABG surgery, MRP4 is upregulated on the plasma membrane and promotes active transport of aspirin out of the platelet (B). The concentration of aspirin in the cytosol falls, and there is less aspirin available to inhibit cyclooxygenase (COX)-1-dependent platelet aggregation. Transport of aspirin out of the cell is reduced by drugs such as dipyridamole that inhibit MRP4-mediated transport. TXA2 ϭ thromboxane A 2 .
